INTRODUCTION

BENOVAT 45MG contains Idebenone which belongs to the group of medicines called nootropic agents. It is indicated for the treatment of various cognitive (e.g. dementia) and behavioural deficits (e.g. decreased volition, altered mental status, emotional disturbances, speech disturbances) associated with cerebrovascular or degenerative disorders like Alzheimer’s disease, cerebral infarction, cerebral hemorrhage or cerebral arteriosclerosis in adult patients. It also improves memory, learning, thinking, volition and attention in these patients.

Idebenone improves cognitive and behavioural defects by protecting the brain cells against the oxidative tissue damage caused by free radicals. Your doctor will decide the correct dose and duration for you depending upon your age, weight and health condition. Do not stop taking this medicine abruptly without consulting your doctor, as it may leads to worsening of your existing condition.

This medicine is generally safe and is well tolerated. However, it may cause mild nausea, diarrhea or headache in few individuals. Contact your doctor if any of the symptoms bothers you. Before taking this medicine, inform your doctor if you have any kidney or liver disease. BENOVAT 45MG is not recommended for use in pregnant or lactating women and in children due to lack of safety data. Consult your doctor before taking.

USES OF BENOVAT 45MG

• Treats cognitive and behavioural deficits in patients with chronic cerebrovascular or degenerative disorders

HOW BENOVAT 45MG WORKS

Idebenone is a powerful antioxidant. It improves cognitive and behavioural defects by protecting the brain cells against the oxidative tissue damage caused by free radicals. It also helps in the stimulation of ATP formation which increases energy production required for mitochondrial function and improves your memory and attention.

DIRECTIONS FOR USE

Take this medicine as directed by your physician. Swallow the medicine as whole with a sip of water. Do not crush or chew the medicine. Your doctor will decide the correct dose and duration for you depending upon your age, weight and health condition. Continue to take this medicine, as long as your doctor tells you to do so, to obtain better results.

SIDE EFFECTS OF BENOVAT 45MG

HOW TO MANAGE SIDE EFFECTS

Nausea:

Try taking this medicine with, or just after meals. Stick to simple meals. Do not eat rich or spicy food.

Diarrhea:

Drink lots of fluids, such as water or juice, to avoid dehydration. Do not take any medicines without speaking to a doctor.

Headache:  

Rest and drink plenty of fluids. Do not drink too much alcohol. Ask your doctor to recommend a painkiller.

WARNING & PRECAUTIONS

INTERACTIONS

Tell your doctor about all the medicines you use, including non-prescription and prescription medicines and herbal supplements.

SYNOPSIS

MORE INFORMATION

• Keep out of reach of children
• Store at room temperature

FAQs ABOUT BENOVAT 45MG

Is BENOVAT 45MG safe?

Yes. This medicine is generally safe and is well tolerated. However, it may cause mild nausea, diarrhea or headache in few individuals. Contact your doctor if any of the symptoms bothers you.

Can BENOVAT 45MG be used for skin?

No. Although it has antioxidant properties, this medicine is only used to protect brain cells from oxidative damage caused due to various cerebral pathologies. Consult your doctor before using any medicine for skin.

Can BENOVAT 45MG be used during pregnancy?

No. This medicine is strictly not recommended for use in pregnant women. Consult your doctor before taking.

REFERENCES

1. Harsh Mohan. The Nervous System. Textbook of Pathology. 6th Edition. 2010. Page – 879.

2. H Gutzmann, D Hadler. Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study. NIH National Library of Medicine, National center for biotechnology information. Pubmed.gov. 1998. [Accessed 25th January 2021] https://pubmed.ncbi.nlm.nih.gov/9850939/

3. Mario Lingetti, Francesco Antonio Porfido, Mario Ciarimboli, Ugo Oliviero, Manlio Cocozza, Vincenzo Coto, Domenico Policicchio, Saverio Carifi, Efrem Piermatteo, Rosanna Lombardi, Emilio Tranfaglia and Francesco Di Grazia. Evaluation of the clinical efficacy of idebenone in patients affected by chronic cerebrovascular disorders. ScienceDirect. November–December 1992. [Accessed 25th January 2021] https://www.sciencedirect.com/science/article/abs/pii/016749439290058C

4. Umberto Senin, Lucilla Parnetti, Giuseppe Barbagallo-Sangiorgi, Luisa Bartorelli, Vittorio Bocola, Antonio Capurso, Marco Cuzzupoli, Mario Denaro, Vincenzo Marigliano, Aldo E.Tammaro and Mario Fioravanti.  Idebenone in senile dementia of Alzheimer type: A multicentre study. ScienceDirect. November–December 1992. [Accessed 25th January 2021] https://www.sciencedirect.com/science/article/abs/pii/016749439290060H

5. Takeda Italia Farmaceutici S.p.A. European Medical Agency (EMA). Raxone. May 1993. [Accessed 25th January 2021] https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-raxone_en.pdf

6. Central Drugs Standard Control Organization (CDSCO). Idebenone tablets. [Revised on September 1999] [Accessed 25th January 2021] https://cdscoonline.gov.in/CDSCO/Drugs